Translate page

NICE Guidance on the use of imatinib 

NICE - National Institute for Health and Care Excellence
Guidance on the use of imatinib for chronic myeloid leukaemia
Issued October 2003; last modified January 2012

Click here to view the NICE guidance

ESMO Guidelines

Chronic Myeloid Leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
Baccarani M et al. Annals of Oncology 2012;23(7):72-77

Click here to view the full publication

Patient-friendly summary of the 2013 ELN Guidelines 

A working group of CML patients from the CML Advocates Network, advised by medical experts, has developed a summary of the 2013 ELN recommendations in a patient-friendly language. This summary aims to help CML patients to discuss disease management and treatment choices with their doctors.

Available in 17 languages 

The patient-friendly summary is currently available in 17 different languages including Arabic, Bulgarian, Chinese, Danish, Dutch, English, French, German, Hebrew, Italian, Polish, Portuguese, Russian, Serbian, Spanish and Turkish.

Access the summaries on the website of the CML Advocates Network  

 

NCCN Guidelines 

Chronic Myelogenous Leukemia
National Comprehensive Cancer Network
Version 1.2017

Click here to view the NCCN Guidelines  

Once registered you will get a copy of the guidelines for your personal use only.

About NCCN

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.

International BFM Group (iBFM):
Managing children with CML

Managing children with chronic myeloid leukaemia (CML)
Recommendations for the management of CML in children and young people up to the age of 18 years
De la Fuente J et al. Br J of Haematol 2014;167:33-47.

Click here to view the full publication here 

Executive Summary:

Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that in adults.

ELN Guidelines

European LeukemiaNet recommendations for the management of chronic myeloid leukemia 2013

Baccarani M et al. Blood 2013;122(6):872-884.

Click here to view a summary of the current ELN guidelines 

Executive Summary:

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009.